Your Yourlocation: Home > Tiotropium bromide(136310-93-5) for the treatment of asthma in adolescents

Summary: Asthma is a common disease that affects millions of people. Despite receiving guideline treatment with inhaled corticosteroids (ICS) with or without a long-acting β2-agonist (LABA), some patients remain symptomatic or have suboptimal lung function. Therefore, additional treatment is needed to improve the need for asthma control. The long-acting anticholinergic tiotropium bromide(136310-93-5) delivered via the Respimat Inhaler is approved for asthma treatment in the European Union, the United States and other countries. Phase III studies in adults have shown that tiotropium improves lung function and asthma control and is comparable in safety to placebo.

Areas covered: Clinical trials of adolescent patients (12-17 years) with moderate or severe symptomatic asthma indicate that tiotropium bromide(136310-93-5) Respimat as an additive to ICS, with or without other maintenance treatment, is a well tolerated and effective Bronchodilators, which show trends in improving asthma control, are similar to data for adult patients.

Expert opinion: tiotropium bromide(136310-93-5) may be useful as an additional maintenance treatment or in high-dose ICS with or without LABA; however, further data are needed to directly compare ICS plus tiotropium to ICS plus LABA in adolescents with symptomatic asthma and to establish long-term effects on the airway model.

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved